OPSUMIT® (macitentan) resources
On this page you will find useful information regarding which patients should be initiated on OPSUMIT®, guidance on prescribing and administering OPSUMIT®, access to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines and 2018 World Symposium on Pulmonary Hypertension proceedings, and recommendations for screening and diagnosing patients with scleroderma or congenital heart disease (CHD) and suspected pulmonary arterial hypertension (PAH).
Prescribing OPSUMIT®
Access the OPSUMIT® SmPC and patient information leaflet.
PAH guidelines and organisations
Component not published? componentType is undefined.
Component not published? componentType is undefined.
Component not published? componentType is undefined.
Identifying PAH in patients with scleroderma
Component not published? componentType is undefined.
Component not published? componentType is undefined.
Identifying PAH in patients with CHD
Learn how PAH can impact patients with CHD.
Learn about the investigation and referral pathways for patients with CHD and suspected PAH.
Continue reading
Discover how OPSUMIT® can provide a range of benefits for patients with PAH.[1][2][3][4]
OPSUMIT® has a well-characterised and generally manageable safety profile.[1][5]
Component not published? componentType is undefined.
CHD, congenital heart disease; ERS, European Respiratory Society; ESC, European Society of Cardiology; PAH, pulmonary arterial hypertension; PHA, Pulmonary Hypertension Association; WSPH, World Symposium on Pulmonary Hypertension
CP-220224 ∣ June 2021
OPSUMIT® PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING
